4.1 Article

Deep Brain Stimulation of the Nucleus Accumbens/Ventral Capsule for Severe and Intractable Opioid and Benzodiazepine Use Disorder

Journal

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
Volume 29, Issue 2, Pages 210-215

Publisher

AMER PSYCHOLOGICAL ASSOC
DOI: 10.1037/pha0000453

Keywords

deep brain stimulation; neuromodulation; addiction; opioid; benzodiazepine

Funding

  1. National Institutes of Health (NIH) through the NIH HEAL Initiative [UG3 DA047714]
  2. National Institute of General Medical Sciences of the NIH [U54GM104942]

Ask authors/readers for more resources

This study evaluated the safety of DBS for substance use disorder and its effects on substance use, craving, emotional symptoms, and frontal/executive functions. The results showed that DBS of the NAc/VC was safe and effective in reducing substance use and craving, as well as improving frontal and executive functions. Confirmation of these findings with future studies is needed.
Given high relapse rates and the prevalence of overdose deaths, novel treatments for substance use disorder (SUD) are desperately needed for those who are treatment refractory. The objective of this study was to evaluate the safety of deep brain stimulation (DBS) for SUD and the effects of DBS on substance use, substance craving, emotional symptoms, and frontal/executive functions. DBS electrodes were implanted bilaterally within the Nucleus Accumbens/Ventral anterior internal capsule (NAc/VC) of a man in his early 30s with >10-year history of severe treatment refractory opioid and benzodiazepine use disorders. DBS of the NAc/VC was found to be safe with no serious adverse events noted and the participant remained abstinent and engaged in comprehensive treatment at the 12-week endpoint (and 12-month extended follow-up). Using a 0-100 visual analog scale, substance cravings decreased post-DBS implantation; most substantially in benzodiazepine craving following the final DBS titration (1.0 +/- 2.2) compared to baseline (53.4 +/- 29.5; p < .001). A trend toward improvement in frontal/executive function was observed on the balloon analog risk task performance following the final titration (217.7 +/- 76.2) compared to baseline (131.3 +/- 28.1, p = .066). FDG PET demonstrated an increase in glucose metabolism in the dorsolateral prefrontal and medial premotor cortices at the 12-week endpoint compared to post-surgery/pre-DBS titration. Heart Rate Variability (HRV) improved following the final titration (rMSSD = 56.0 +/- 11.7) compared to baseline (19.2 +/- 8.2; p < .001). In a participant with severe, treatment refractory opioid and benzodiazepine use disorder, DBS of the NAc/VC was safe, reduced substance use and craving, and improved frontal and executive functions. Confirmation of these findings with future studies is needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available